Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CNSI Cambridge Neuroscience -- Ignore unavailable to you. Want to Upgrade?

To: limit who wrote (534)	2/7/2000 5:30:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 675

Cambridge NeuroScience Reports Fourth Quarter and Year-End 1999 Financial Results biz.yahoo.com Our year-end financials reflect the Company's strategic initiative to minimize our operating expenses while maximizing the resources dedicated to developing our lead products. Collaborations with both Allergan and Bayer, in the areas of ophthalmic products and neurodegenerative diseases, respectively, continue to progress,'' said Harry Wilcox, President and CEO of Cambridge NeuroScience, Inc. ''We are also excited about advancing our compound, CNS 5161, into Phase II trials for the treatment of neuropathic pain, using both transdermal and intravenous formulations. We anticipate reporting preliminary data from a Phase II intravenous trial by year end 2000.